Cases & Deals

Celgene establishes global patent portfolio for its brands REVLIMID®, POMALYST®, OTEZLA®, VIDAZA®, ABRAXANE® and ISTODAX®

Clients Celgene Corporation

Jones Day assists Celgene Corporation in the establishment of its global patent portfolio related to lenalidomide (REVLIMID®), pomalidomide (POMALYST®), apremilast (OTEZLA®), azacitidine (VIDAZA®), ABRAXANE® and romidepsin (ISTODAX®) for the treatments of cancer and immune, inflammatory conditions.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.